paola fazi

chief executive officer

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Paola Fazi is the Chief Executive Officer at Fondazione Gimema Onlus, Italy. Her research focuses on hematologic malignancies, with recent publications exploring new therapies for acute lymphoblastic leukemia and acute myeloid leukemia, as well as patient-reported outcomes in oncology. She has been involved in multicenter clinical trials assessing the impacts of minimal residual disease and the effects of the COVID-19 pandemic on clinical management of hematologic disorders.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Bernhard Holzner

Prof.

Medical University of Innsbruck

AUSTRIA

View details

Sabina Chiaretti

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

paola fazi

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study

A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: Final results of the GIMEMA LAL1509 protocol

Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

AMELIORATE: early intensification in <i>FLT3</i>-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.

Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.

Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors.

Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis.

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey.

Collaborators (2)

Bernhard Holzner

Sabina Chiaretti

Make your next move.